This review discusses the recent progress in understanding SWI/SNF alterations in ovarian cancer and specifically focuses on: (i) <i>ARID1A</i> mutation in endometriosis-associated clear cell and endometrioid histologic subtypes of ovarian cancer; (ii) <i>SMARCA4</i> mutation in small cell carcinoma of the ovary, hypercalcemic type; and (iii) amplification/upregulation of <i>CARM1</i>, a regulator of BAF155, in high-grade serous ovarian cancer.